Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics Holdings, Inc. が 2026年8月11日 に発表した内容

企業自身の 8-K から。

株価の反応

発表は引け後か寄り前に出るため、ここでの値動きは次の取引日のものです。

Hemab Therapeutics Holdings, Inc. の事業内容

Glanzmann thrombasthenia (GT) is a severe bleeding disorder marked by debilitating, sometimes life-threatening bleeding episodes. Results from an international natural history study (Glanzmann’s 360) revealed the substantial burden of this disease: 88% of the 117 participants reported at least one bleed in the previous week with 65% requiring a bleed-related hospital visit in the prior six months. These bleeding episodes significantly impacted patients’ mental health and quality of life, with over 80% having missed work or school, over 50% facing limitations in attending social events, and over 50% experiencing restrictions in travel. To date, there are no approved prophylactic treatment options for GT.

発表資料の末尾に記載された、企業自身による説明です。